Selected research
Industry Growth & Trends
Global Repurposed Drugs Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Repurposed Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Repurposed Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Repurposed Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Repurposed Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Repurposed Drugs market include Teva, Johnson & Johnson, Novartis, Mylan, Pfizer, GSK, R-Pharma, Glenmark and Fujifilm, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Repurposed Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Repurposed Drugs market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Repurposed Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Repurposed Drugs.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Repurposed Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Repurposed Drugs Market by Company
Teva
Johnson & Johnson
Novartis
Mylan
Pfizer
GSK
R-Pharma
Glenmark
Fujifilm
Dr. Reddy
ChemRar Group
Bausch Health
Repurposed Drugs Segment by Type
Generic Drugs
Clinical Trial Failed Drugs
Repurposed Drugs Segment by Application
Cardiovascular Diseases
Mental Illness
Cancer
Other
Repurposed Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Repurposed Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Repurposed Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Repurposed Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Repurposed Drugs companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Generic Drugs
- Clinical Trial Failed Drugs
Applications
- Cardiovascular Diseases
- Mental Illness
- Cancer
- Other
Companies covered
- Teva
- Johnson & Johnson
- Novartis
- Mylan
- Pfizer
- GSK
- R-Pharma
- Glenmark
- Fujifilm
- Dr. Reddy
- ChemRar Group
- Bausch Health
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Repurposed Drugs Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Repurposed Drugs Market Size by Region (2021-2032)
- 1.4.1 Global Repurposed Drugs Market Size by Region (2021-2026)
- 1.4.2 Global Repurposed Drugs Market Size by Region (2027-2032)
- 1.5 Key Regions Repurposed Drugs Market Size (2021-2032)
- 1.5.1 North America Repurposed Drugs Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Repurposed Drugs Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Repurposed Drugs Market Size Growth Rate (2021-2032)
- 1.5.4 South America Repurposed Drugs Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Repurposed Drugs Market Size Growth Rate (2021-2032)
2 Repurposed Drugs Market by Type
- 2.1 Type Introduction
- 2.1.1 Generic Drugs
- 2.1.2 Clinical Trial Failed Drugs
- 2.2 Global Repurposed Drugs Market Size by Type
- 2.2.1 Global Repurposed Drugs Market Size Overview by Type (2021-2032)
- 2.2.2 Global Repurposed Drugs Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Repurposed Drugs Market Size Forecasted by Type (2027-2032)
- 2.3 Global Repurposed Drugs Market Size by Regions
- 2.3.1 North America Repurposed Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Repurposed Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Repurposed Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Repurposed Drugs Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Repurposed Drugs Market Size Breakdown by Type (2021-2026)
3 Repurposed Drugs Market by Application
- 3.1 Type Introduction
- 3.1.1 Cardiovascular Diseases
- 3.1.2 Mental Illness
- 3.1.3 Cancer
- 3.1.4 Other
- 3.2 Global Repurposed Drugs Market Size by Application
- 3.2.1 Global Repurposed Drugs Market Size Overview by Application (2021-2032)
- 3.2.2 Global Repurposed Drugs Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Repurposed Drugs Market Size Forecasted by Application (2027-2032)
- 3.3 Global Repurposed Drugs Market Size by Regions
- 3.3.1 North America Repurposed Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Repurposed Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Repurposed Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Repurposed Drugs Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Repurposed Drugs Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Repurposed Drugs Industry Trends
- 4.2 Repurposed Drugs Industry Drivers
- 4.3 Repurposed Drugs Industry Opportunities and Challenges
- 4.4 Repurposed Drugs Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Repurposed Drugs Revenue (2021-2026)
- 5.2 Global Repurposed Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Repurposed Drugs Key Company Headquarters & Area Served
- 5.4 Global Repurposed Drugs Company, Product Type & Application
- 5.5 Global Repurposed Drugs Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Repurposed Drugs Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Repurposed Drugs Players Market Share by Revenue in 2025
- 5.6.3 2025 Repurposed Drugs Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Teva
- 6.1.1 Teva Company Information
- 6.1.2 Teva Business Overview
- 6.1.3 Teva Repurposed Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Teva Repurposed Drugs Product Portfolio
- 6.1.5 Teva Recent Developments
- 6.2 Johnson & Johnson
- 6.2.1 Johnson & Johnson Company Information
- 6.2.2 Johnson & Johnson Business Overview
- 6.2.3 Johnson & Johnson Repurposed Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Johnson & Johnson Repurposed Drugs Product Portfolio
- 6.2.5 Johnson & Johnson Recent Developments
- 6.3 Novartis
- 6.3.1 Novartis Company Information
- 6.3.2 Novartis Business Overview
- 6.3.3 Novartis Repurposed Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Novartis Repurposed Drugs Product Portfolio
- 6.3.5 Novartis Recent Developments
- 6.4 Mylan
- 6.4.1 Mylan Company Information
- 6.4.2 Mylan Business Overview
- 6.4.3 Mylan Repurposed Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 Mylan Repurposed Drugs Product Portfolio
- 6.4.5 Mylan Recent Developments
- 6.5 Pfizer
- 6.5.1 Pfizer Company Information
- 6.5.2 Pfizer Business Overview
- 6.5.3 Pfizer Repurposed Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Pfizer Repurposed Drugs Product Portfolio
- 6.5.5 Pfizer Recent Developments
- 6.6 GSK
- 6.6.1 GSK Company Information
- 6.6.2 GSK Business Overview
- 6.6.3 GSK Repurposed Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 GSK Repurposed Drugs Product Portfolio
- 6.6.5 GSK Recent Developments
- 6.7 R-Pharma
- 6.7.1 R-Pharma Company Information
- 6.7.2 R-Pharma Business Overview
- 6.7.3 R-Pharma Repurposed Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 R-Pharma Repurposed Drugs Product Portfolio
- 6.7.5 R-Pharma Recent Developments
- 6.8 Glenmark
- 6.8.1 Glenmark Company Information
- 6.8.2 Glenmark Business Overview
- 6.8.3 Glenmark Repurposed Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 Glenmark Repurposed Drugs Product Portfolio
- 6.8.5 Glenmark Recent Developments
- 6.9 Fujifilm
- 6.9.1 Fujifilm Company Information
- 6.9.2 Fujifilm Business Overview
- 6.9.3 Fujifilm Repurposed Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Fujifilm Repurposed Drugs Product Portfolio
- 6.9.5 Fujifilm Recent Developments
- 6.10 Dr. Reddy
- 6.10.1 Dr. Reddy Company Information
- 6.10.2 Dr. Reddy Business Overview
- 6.10.3 Dr. Reddy Repurposed Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 Dr. Reddy Repurposed Drugs Product Portfolio
- 6.10.5 Dr. Reddy Recent Developments
- 6.11 ChemRar Group
- 6.11.1 ChemRar Group Company Information
- 6.11.2 ChemRar Group Business Overview
- 6.11.3 ChemRar Group Repurposed Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 ChemRar Group Repurposed Drugs Product Portfolio
- 6.11.5 ChemRar Group Recent Developments
- 6.12 Bausch Health
- 6.12.1 Bausch Health Company Information
- 6.12.2 Bausch Health Business Overview
- 6.12.3 Bausch Health Repurposed Drugs Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Bausch Health Repurposed Drugs Product Portfolio
- 6.12.5 Bausch Health Recent Developments
7 North America
- 7.1 North America Repurposed Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Repurposed Drugs Market Size by Country (2021-2026)
- 7.3 North America Repurposed Drugs Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Repurposed Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Repurposed Drugs Market Size by Country (2021-2026)
- 8.3 Europe Repurposed Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Repurposed Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Repurposed Drugs Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Repurposed Drugs Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Repurposed Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Repurposed Drugs Market Size by Country (2021-2026)
- 10.3 South America Repurposed Drugs Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Repurposed Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Repurposed Drugs Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Repurposed Drugs Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst